Lilly gets USFDA nod for Taltz(ixekizumab) for Pediatric Patients with Moderate to Severe Plaque Psoriasis Medical Dialogues Bureau1 April 2020 7:00 AM GMTIndianapolis: Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Appli...
Eli Lilly delays its clinical trials during Coronavirus pandemic Medical Dialogues Bureau25 March 2020 9:30 AM GMTIndianapolis: Eli Lilly and Company has provided an update on the company's clinical trial activities in light of the COVID-19 pandemic. The company wi...
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for Alopecia Areata Medical Dialogues Bureau19 March 2020 7:26 AM GMTBaricitinib is currently approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).
AbCellera, Eli Lilly join hands for Antibody Therapies for COVID-19 Medical Dialogues Bureau13 March 2020 3:30 AM GMTVancouver and Indianapolis: AbCellera and Eli Lilly and Company have recently announced that they have entered into an agreement to co-develop...
USFDA accepts regulatory submission for tanezumab for management of chronic pain due to osteoarthritis Medical Dialogues Bureau7 March 2020 4:30 AM GMTTanezumab is a monoclonal antibody that is part of an investigational class of non-opioid chronic pain medications known as nerve growth factor (NGF)...
FDA Advisory approves Lilly's CYRAMZA (ramucirumab) for type of lung Cancer Medical Dialogues Bureau1 March 2020 8:30 AM GMTThe ODAC considered the safety and efficacy data from the Phase 3 RELAY trial, which is the basis for the CYRAMZA supplemental Biologics License...
Drugmakers including Novartis, Roche slash prices by 61pc in China to get on reimbursement list Medical Dialogues Bureau29 Nov 2019 3:45 AM GMTSeventy new drugs such as Roche's breast cancer treatment Pertuzumab, sold under the trade name Perjeta, Novartis's dermatitis treatment Omalizumab, br...
Novo Nordisk wins USFDA nod for oral diabetes drug Rybelsus Medical Dialogues Bureau23 Sep 2019 8:46 AM GMTNovo Nordisk did not disclose what it plans to charge for the new oral treatment, called Rybelsus, but said it would be 'competitively priced' with oth...
Mylan gets tentative USFDA nod for generic of Eli Lilly lung cancer drug Alimta Medical Dialogues Bureau31 Aug 2019 4:00 AM GMTAlimta is Lilly's third biggest-selling drug. The Indianapolis-based drugmaker reported second-quarter sales of $577.8 million for the medicine.U.S:...
Lupin unveils generic version of Prozac tablets in US Medical Dialogues Bureau24 Aug 2019 4:15 AM GMTFluoxetine tablet is a generic version of Eli Lilly and Company's Prozac tablets in the same strengths, Lupin said.Mumba: Pharma major Lupin Limited...
Roche names Eli Lilly executive Levi Garraway as chief medical officer Medical Dialogues Bureau20 Aug 2019 3:30 AM GMTLevi Garraway, most recently Eli Lilly's senior vice president, oncology research and development and Lilly research laboratories novel target research...
AbbVie wins USFDA nod for new rheumatoid arthritis drug priced at Rs 41 lakh per year Medical Dialogues Bureau18 Aug 2019 4:06 AM GMTA four-week supply of Humira, the world's best-selling medicine, has a list price of about $5,174, amounting to more than $60,000 for a year.U.S:...
